Zentalis Pharmaceuticals prices 23M-share offering at $3.50, raising $80.5M gross for clinical development

Filed August 14, 2026 · ~1 min read

Key Changes

• high

  Zentalis is selling 23,000,000 new shares at $3.50 per share, with gross proceeds of $80.5 million before underwriting discounts and expenses.

  The Offering verify on EDGAR →
• high

  Net proceeds to the company are estimated at $75.1 million, or $86.4 million if the underwriters' option to purchase up to 3,450,000 additional shares is fully exercised.

  Use of Proceeds verify on EDGAR →
• high

  The company intends to use net proceeds to fund clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostics, pre-commercial activities, and general corporate purposes.

  Use of Proceeds verify on EDGAR →